On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


ChineseInvestors.com Inc. (CIIX) Positioned as First Company to Market CBD Products to Chinese-Speaking Consumers

  • ChineseInvestors.com offers first-rate financial information and innovative CBD products
  • CBD is poised to become one of China’s largest industries over the next decade
  • CIIX is at the vanguard of what may become the world’s largest CBD market

Offering an array of investor education products and services, ChineseInvestors.com Inc. (OTCQB: CIIX) provides web-based, real-time financial information in Chinese language character sets. Not only is it a top financial information website for Chinese-speaking investors in the U.S. and China, CIIX is also becoming a major player in the emerging CBD (cannabidiol) market for CBD-based nutrition and health products in China. The company is focusing back on its original mission of providing financial information and services to the larger Chinese community in the U.S. and globally while exploring major CDB market opportunities. As the disposable income of the average Chinese consumer continues to grow, CIIX is making moves to penetrate the steadily growing Chinese CBD market.

Through wholly owned enterprise CBD Biotech Inc., CIIX is implementing its CBD initiatives. At present, CIIX is at the vanguard of what may become be the globe’s largest CBD market: China (www.CIIXInfo.com). The company recognizes the untapped CBD market for Chinese-speaking individuals, specifically in the health care sector, which is expected to grow by as much as 10 percent per year. Due to a higher spending power from consumers, China’s demand for medicinal products such as those made from hemp-based CBD has risen. Analysts foresee China’s CBD market reaching over $20 billion by 2022, and CIIX is uniquely positioned to meet this consumer demand. CIIX is hoping for a Nasdaq IPO of CBD Biotech late in FY2019 or early in 2020.

CIIX developed its unique niche by concentrating on the Chinese-speaking markets where it has historically generated success. This bodes well for its CBD strategy. The company has created a three-year development plan to take advantage of mainland China’s interest in CBD-infused health and wellness products. Realizing that CBD is anticipated to become one of China’s largest industries over the next 10 years with a potential market of close to two billion people, CIIX’s strategy aims to educate consumers about the benefits of CBD oil.

CIIX is no stranger to the CBD market, as it operated one of the first Chinese-language CBD stores online. It also opened its initial CBD pop-up kiosk in Glendale Galleria Mall in California. This past February, CIIX launched its rebranded CBD consumer product line and consolidated its retail ecommerce outlets into a single site, www.365CWC.com. CIIX now offers consumers opt Hemp, which includes products infused with industrial hemp derived CDB. It additionally offers opt2mist(TM), a spray vitamin product line featuring full spectrum hemp-derived CBD-infused formulas.

CBD Biotech has its own product lines specifically designed for the Chinese market internationally. These include CBD Biotech’s Live Oxygen Series and its Magic Hemp Series.

The numbers show support for CIIX’s CBD-driven direction. Hemp and CBD sales were a key driver in its recent robust quarterly performance. For the third quarter of FY2019, ended February 28, 2019, CIIX reported total revenue of $1.4 million. This represents an increase of 81 percent from the same quarter of FY2018. Hemp and CBD sales increased almost 600 percent in Q3, reaching $1.1 million. Recently, CBD Biotech was a featured exhibitor at the Vietnam Expo, where it introduced its hemp-infused skincare line and hemp wine, which is expected to add to future sales growth.

CIIX continues to focus on investor education products and services and compelling CDB opportunities. The company offers investors the potential for portfolio gain because of its focus on highly diversified revenue streams. With its emphasis on premier financial information as well as high quality hemp-based CBD products, CIIX continues its march toward greater growth and profits for all its stakeholders.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

May 22, 2020

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a […]

Rotate your device 90° to view site.